OssDsign (OSSD) Financial Stockholm summary
Event summary combining transcript, slides, and related documents.
Financial Stockholm summary
21 Oct, 2026Investor meeting
Presentation scheduled for Jan. 27 at Hotel Anglais in Stockholm, hosted by Financial Stockholm with Aktiespararna Stockholm Vasa.
Participation alongside other presenters, with latest updates to be shared at the investor meeting.
Products and technology
Develops regenerative implants for bone defects, including patient-specific solutions for cranial defects and facial reconstruction.
Technology combines clinical knowledge with proprietary materials expertise, developed through collaboration between Karolinska University Hospital and Uppsala University’s Ångström Laboratory.
Partial view of Summaries dataset, powered by Quartr API
Latest events from OssDsign
- Seasonal softness cut Q3 sales as gross margin held up and Catalyst evidence advanced.OSSD
Q3 2026 - ASCENT25 targets SEK 300–400 million in 2025 sales and operating cash flow positivity in 2024.OSSDStrategy Update
- High fusion rates, U.S. market focus, and sales force overhaul support ambitious 2028 growth targets.OSSDDNB Carnegie Micro Cap Day Conference
- Q2 sales declined year-over-year, but restructuring and innovation support future growth.OSSDQ2 2026
- Property-focused group targets recurring revenues and European growth, leveraging strong cash reserves.OSSDABGSC Investor Days
- Q1 revenue declined 17.1% in SEK and 3.6% in USD, but H2 momentum is expected.OSSDQ1 2026
- Sales up 45% to SEK 180.2M, 96.3% margin, U.S. expansion, aiming for SEK 400M by 2028.OSSDQ4 2025
- Q3 2024 delivered 114% sales growth, 96.9% gross margin, and narrowed losses.OSSDQ3 2024
- Q2 net sales up 143%, gross margin at 93.2%, and major U.S. contracts secured.OSSDQ2 2024